New stock news | Hainan Pharmaceutical Hong Kong stock IPO and domestic unlisted shares "full circulation" approved by the China Securities Regulatory Commission.

On May 9, the International Cooperation Department of the China Securities Regulatory Commission issued a "Record Filing Notice on Overseas Issuance and Listing of South Ocean Pharma Tech Co., Ltd. and Full Circulation of Unlisted Shares in China". South Ocean Pharma plans to issue no more than 19,324,600 ordinary shares for overseas listing and listing on the Hong Kong Stock Exchange. 32 shareholders of the company intend to convert a total of 90,236,375 unlisted shares in China into overseas listed shares, and list them for circulation on the Hong Kong Stock Exchange. According to the prospectus, South Ocean Pharma is an integrated pharmaceutical research and manufacturing company that provides CXO services; in addition, the company owns a proprietary product pipeline, primarily commercialized through pharmaceutical technology transfer. According to a Frost & Sullivan report, during the reporting period and up to the last practicable date (November 2, 2025), South Ocean Pharma ranked second among CXO service providers engaged in drug technology transfer in China in terms of the number of approved clinical trials and marketing licenses. According to the same source, South Ocean Pharma also ranked second in the total number of clinical trial and marketing license applications submitted during the same period. South Ocean Pharma operates one of the most comprehensive CXO platforms in the industry, covering the entire chain of drug discovery, CMC, preclinical and clinical development, registration and validation, and commercial production. The company provides end-to-end or modular CRO and CMO solutions covering drug R&D and CMC, clinical and bioequivalence testing services, registration applications, and contract manufacturing. As of December 31, 2022, 2023, and 2024, and June 30, 2025, South Ocean Pharma had 242, 331, 383, and 398 ongoing CXO projects respectively.